Genome Sequence and Characterization of Acinetobacter Phage DMU1

Bailey M Pehde1, Devon Niewohner1, Faithe E Keomanivong1

  • 1Department of Microbiology and Immunology, College of Osteopathic Medicine, Des Moines University, Des Moines, Iowa, USA.

PHAGE (New Rochelle, N.Y.)
|September 23, 2022
PubMed

Insights

Researchers characterized Acinetobacter phage DMU1, a siphophage related to SH-Ab 15497, for potential therapeutic use against multidrug-resistant Acinetobacter baumannii infections. DMU1 shows a limited host range, infecting only specific A. baumannii strains.

Area of Science:

  • Microbiology
  • Virology
  • Genomics

Background:

  • Multidrug-resistant Acinetobacter baumannii infections pose a significant health threat due to treatment failures.
  • There is a growing interest in bacteriophage therapy as an alternative treatment for resistant bacterial infections.

Purpose of the Study:

  • To characterize Acinetobacter phage DMU1, isolated from activated sludge, for its potential as a therapeutic agent.
  • To determine the morphological, genomic, and host range characteristics of Acinetobacter phage DMU1.

Main Methods:

  • Electron microscopy for morphological analysis.
  • Genome sequencing and comparative genomics for phylogenetic placement.
  • Host range analysis to identify susceptible bacterial strains.

Main Results:

  • Acinetobacter phage DMU1 exhibits morphology consistent with the Siphoviridae family.
  • Genomic analysis reveals DMU1 is a siphophage most closely related to Acinetobacter phage SH-Ab 15497.
  • Host range analysis indicates DMU1 infects only specific strains of Acinetobacter baumannii, including ATCC19606 and ATCC17978.

Conclusions:

  • Acinetobacter phage DMU1 is a siphophage with potential for targeted therapy against specific Acinetobacter baumannii strains.
  • Further research is warranted to explore the therapeutic efficacy and broader applications of DMU1.